Endo's Presentation on Peyronie's Disease at Key Health Event
Endo, Inc. (OTCQX: NDOI) is set to unveil significant research related to Peyronie's disease during the International Society for the Study of Women's Sexual Health (ISSWSH) and the International Society for Sexual Medicine (ISSM) joint meeting. This event brings together healthcare professionals focused on women's sexual health to foster knowledge and improve patient care.
The presentation, led by Dr. Irwin Goldstein, a urologist and esteemed advocate for women's health, will discuss the findings from a recent survey aimed at understanding the emotional and psychological effects that Peyronie’s disease can have on the female partners of men affected by this condition. Dr. Goldstein expressed enthusiasm about sharing insights gathered from this survey. "We're eager to explore the awareness and practices of healthcare providers, which will help us uncover ways to enhance support for both medical professionals and their patients," he remarked.
Focus on Women's Sexual Health Providers
The presented research titled, Development of a Survey to Assess Women's Sexual Health Providers' Awareness and Approach Toward Peyronie's Disease and the Impact on the Female Sexual Partner, features contributions from a range of professionals. This collaboration emphasizes a collective understanding of how Peyronie’s disease affects relationships and sexual satisfaction.
Expert Authors Behind the Research
The work includes prominent figures such as Dr. Sue W. Goldstein, CSE, CCRC, IF, Dr. Rose Hartzell, PhD, EdS, and Dr. Tami Rowen, MD among others. Each expert brings unique insights and research background to the table, aiming to enhance treatment protocols and provider education about this prevalent condition affecting many.
Understanding Peyronie’s Disease
Peyronie's disease is characterized by the buildup of fibrous scar tissue within the penis, resulting in a curvature that can cause discomfort during intimacy. It is estimated that this condition affects approximately 1 in 10 men in the U.S. Despite its prevalence, many men hesitate to seek help due to embarrassment, leading to underdiagnosis and under-treatment.
The impact of Peyronie’s disease extends beyond the individual diagnosed; it can substantially affect the sexual health and satisfaction of female partners. Studies indicate that sexual function can diminish for partners of men dealing with this condition, highlighting the need for increased awareness and physician training about the emotional and relational dimensions of Peyronie’s disease.
About Endo and Its Commitment to Health
Endo is a dynamic specialty pharmaceutical company dedicated to developing innovative therapies that enhance patients’ quality of life. With a team passionate about collaboration, Endo strives to address critical health issues and deliver essential medicines to communities.
Learn more about Endo's endeavors in enhancing health solutions and its commitment to patient care by visiting www.endo.com or following them on social media.
Frequently Asked Questions
1. What is the purpose of Endo's presentation at the ISSWSH meeting?
The presentation aims to discuss a survey that assesses healthcare providers' understanding of Peyronie's disease and its impact on female partners.
2. Who is leading the presentation at the conference?
The presentation is led by Dr. Irwin Goldstein, a urologist with significant expertise in women's sexual health.
3. What is Peyronie’s disease?
Peyronie’s disease is a condition where scar tissue forms in the penis, causing curvature that can lead to discomfort during sexual activity.
4. How many men are estimated to be affected by Peyronie's disease?
It is estimated that Peyronie’s disease affects approximately 1 in 10 men in the United States.
5. What is Endo's mission?
Endo is committed to transforming patient insights into life-enhancing therapies through collaboration and innovation in the healthcare sector.
